CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS

Teru Hideshima

Functional and biologic significance of deacetylase3 inhibition in myeloma

Multiple myeloma and immunoproliferative diseases

William Figg

Using Clinical Pharmacology Principles to Develop New Anticancer Therapies

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Kelvin P. Lee

CD28-mediated Regulation of Multiple Myeloma Cell Proliferation and Survival

Multiple myeloma and immunoproliferative diseases

Wei Gu

HAUSP inhibitors in p53-wild type and p53-mutant tumors

Multiple myeloma and immunoproliferative diseases

Robert Zygmunt Orlowski

Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma

Multiple myeloma and immunoproliferative diseases

Elad Ziv

Influence of germ line genetic variation on myeloma progression and survival

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Jens G Lohr

Determining the mutational landscape of circulating multiple myeloma cells

Multiple myeloma and immunoproliferative diseases

Pathology

Kelvin P Lee

CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Tracy L Mcgaha

The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDSC development

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology